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Abstract
Background In order to grow the potential therapeutic armamentarium in the cachexia domain of supportive oncology,
there is a pressing need to develop suitable biomarkers and potential drug targets. This pilot study evaluated several potential
candidate biomarkers in skeletal muscle biopsies from a cohort of upper gastrointestinal cancer (UGIC) patients.
Methods One hundred seven patients (15 weight-stable healthy controls (HC) and 92 UGIC patients) were recruited. Mean
(standard deviation) weight-loss of UGIC patients was 8.1 (9.3%). Cachexia was deﬁned as weight-loss ≥5%. Rectus abdominis
muscle was obtained at surgery and was analysed by western blotting or quantitative real-time–polymerase chain reaction.
Candidate markers were selected according to previous literature and included Akt and phosphorylated Akt (pAkt, n = 52),
forkhead box O transcription factors (n = 59), ubiquitin E3 ligases (n = 59, control of muscle anabolism/catabolism), BNIP3
and GABARAPL1 (n = 59, as markers of autophagy), myosin heavy-chain (MyHC, n = 54), dystrophin (n = 39), β-dystroglycan
(n = 52), and β-sarcoglycan (n = 52, as markers of structural alteration in a muscle). Patients were followed up for an average
of 1255 days (range 581–1955 days) or until death. Patients were grouped accordingly and analysed by (i) all cancer patients
vs. HC; (ii) cachectic vs. non-cachectic cancer patients; and (iii) cancer patients surviving ≤1 vs. >1 year post operatively.
Results Cancer compared with HC patients had reduced mean (standard deviation) total Akt protein [0.49 (0.31) vs. 0.89
(0.17), P = 0.001], increased ratio of phosphorylated to total Akt [1.33 (1.04) vs. 0.32 (0.21), P = 0.002] and increased expression
of GABARAPL1 [1.60 (0.76) vs. 1.10 (0.57), P = 0.024]. β-Dystroglycan levels were higher in cachectic compared with non-
cachectic cancer patients [1.01 (0.16) vs. 0.87 (0.20), P = 0.007]. Survival was shortened in patients with low compared with
high MyHC levels (median 316 vs. 1326 days, P = 0.023) and dystrophin levels (median 341 vs. 660 days, P = 0.008).
Conclusions The present study has identiﬁed intramuscular protein level of β-dystroglycan as a potential biomarker of can-
cer cachexia. Changes in the structural elements of muscle (MyHC or dystrophin) appear to be survival biomarkers.
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Introduction
Cancer cachexia represents an important yet often under-
appreciated cause of patient morbidity and mortality. It is ‘a
multifactorial syndrome deﬁned by an ongoing loss of skeletal
muscle mass (with or without loss of fat mass) that cannot be
fully reversed by conventional nutritional support and leads to
progressive functional impairment’.1 Cachexia is due to a
combination of reduced food intake and metabolic change.
The prevalence of cachexia varies with tumour type and stage
and may also vary with the genotype of the host.2 Affected
individuals face increased risks of treatment failure (be it
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chemotherapy, radiotherapy, or surgery), increased risks of
treatment side-effects, and an increased mortality rate.1,3
Cachexia in its advanced phase (where patients may have
lost 20–30% of their bodyweight) is easily identiﬁed, but by this
stage, it is often impossible to undertake any realistic form of
multimodal rehabilitation. Thus, it would be useful to identify
patients who are at risk or in the early phase of cancer cachexia
so that targeted intervention can be instituted. An early inter-
vention approach has been hampered by a limited understand-
ing of the molecular pathways implicated in human cancer
cachexia along with a lack of validated biomarkers. For exam-
ple, although elevated serum C-reactive protein (CRP) is a ro-
bust indicator of systemic inﬂammation and has been linked
to cancer-associated hypermetabolism, reduced food intake
and shortened survival,4 in a multivariate model of weight-loss
in upper gastrointestinal cancer (UGIC) patients, the estimate
of effect size on degree of weight-loss for CRP was only 34%.5
Loss of skeletal muscle has been identiﬁed as the central char-
acteristic of cancer cachexia.1 We hypothesised that either al-
teration in pathways of muscle atrophy or in the components
of muscle itself might provide more robust biomarkers.
Muscle wasting occurs as a result of an imbalance between
protein synthesis and degradation. Evidence from animal models
of muscle atrophy suggests that the catabolic ubiquitin protea-
some and autophagy pathways are of key importance.6–10 Despite
this knowledge, there remains limited data relating to human can-
cer cachexia. A few studies have identiﬁed potential biomarkers of
cachexia in various tissue compartments using different method-
ological approaches.2,11–14 Ideally, a biomarker should be assessed
with the minimum of discomfort or complexity to the patient.
However, at the level of biomarker discovery and biomarkers that
can inform pathophysiology or drug targets, more invasive
methods (e.g. muscle biopsies) may be required until a less inva-
sive correlate can be identiﬁed. We sought to identify potential
clinically relevant cachectic biomarkers in skeletal muscle biopsies
from UGIC patients in relation to weight-loss and post-operative
survival. A hypothesis-driven approach was taken, where putative
candidate genes or proteins, selected according to previous litera-
ture, were considered one by one as possible biomarkers.15 Can-
didate markers included Akt and phosphorylated Akt (pAkt),
forkhead box O (FOXO) transcription factors, ubiquitin E3 ligases
(control of muscle anabolism/catabolism),6–8,16,17 BNIP3 and
GABARAPL1 (as markers of autophagy),6,9,18,19 myosin heavy-
chain (MyHC), dystrophin, β-dystroglycan, and β-sarcoglycan
(as markers of structural alteration in a muscle).7,10,20,21
Materials and methods
Subjects
Ninety-two consecutive UGIC patients [with a diagnosis of
oesophago-gastric (n = 56), small bowel (n = 2), pancreatic
(n = 33), or common bile duct (n = 1) malignancy] undergoing
potentially curative surgery were recruited. Sixteen patients
had Stage IV disease, 38 patients had Stage III, 23 patients
had Stage II, and 15 patients had Stage I disease. Patients
(n = 27) who had completed a course of neoadjuvant chemo-
therapy had not received chemotherapy in the 4weeks prior
to surgery/biopsy. No subjects were knowingly taking
anabolic/catabolic agents and had uncontrolled diabetes or
thyroid disorders. The weight-stable healthy controls (HC)
comprised 15 subjects undergoing abdominal surgery for
non-malignant and non-inﬂammatory conditions (e.g. hernia
repair and cholecystectomy). Written informed consent was
obtained from all subjects, and ethical approval was received
from Lothian Research Ethics Committee (UK). UGIC patients
were followed up for an average of 1255 days (range 581–
1955 days) post operatively or until death.
Anthropometry, weight-loss, and performance
status
Body weight was measured in light clothing using a beam
scale (Seca, UK). Height was measured using a standard
wall-mounted measure. The patients’ clinical details were
recorded, and degree of weight-loss from self reported pre-
illness (~6months previously) stable weight was docu-
mented. Patients were classiﬁed as cachectic if they had
weight-loss ≥5%.1 Karnofsky performance score (KPS) was
assessed in each patient by a single observer.
Patient groups
In order to determine if biomarkers were just markers of cancer
in general or bona ﬁde cachexia markers, patients were divided
into groups for analyses as follows: healthy control vs. cancer
and subsequently non-cachectic cancer and cachectic cancer
patients. To assess survival biomarkers, cancer patients were
divided according to survival > or <1 year post operatively.
This cut-off was chosen in line with clinical practice, where it
is generally considered meaningful in terms of surgical and on-
cological outcome and furthermore has recently been advo-
cated by the All Party Parliamentary Group on Cancer.22
Muscle biopsies
All biopsies were taken at the start of an open abdominal sur-
gery under general anaesthesia. Patients had undergone an
overnight fast. The edge of the Rectus abdominis was
exposed, and a 1 cm3 specimen was removed using sharp dis-
section. Tissue samples were quickly cleaned of blood, were
ﬂash frozen in liquid nitrogen, and were stored at !80°C until
further analysis.
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Blood measures
All blood samples were taken following an overnight fast. CRP
level was measured using enzyme-linked immunosorbent
assay (Ely, UK). A CRP ≥5mg/L (the upper limit of normal in
our lab) was considered consistent with the presence of sys-
temic inﬂammation.
Protein isolation
Approximately 20mg of muscle was homogenised in 0.5mL
of lysis buffer [Triton X-100 (1%), NaCl (150mM), Tris–HCl
(50mM), ethylenediaminetetraacetic acid (EDTA, 1mM),
phenylmethylsulfonyl ﬂuoride (1mM), protease inhibitors
(Roche Diagnostics, Basel, Switzerland, 1 tablet per 10mL),
and water to 10mL] using a powergen 125 (Fisher Scientiﬁc,
Waltham, MA, USA) electric homogeniser. Samples were left
on ice for 15min prior to centrifuging at 13 000 rpm for
15min. The supernatant was removed, and protein concen-
tration was determined by comparing equal volumes of
sample solution to known standards using the Lowry method.
Samples were then stored at !80°C.
Nuclear protein extraction (for forkhead box O
transcription factors)
Approximately 20mg of muscle was resuspended in 180μL
of low salt lysis buffer [10mM (4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid, HEPES), 10mM KCl,
1.5mM MgCl2, 0.1mM EDTA, 0.1mM ethylene glycol
tetraacetic acid (EGTA), 1mM dithiothreitol (DTT), 0.5mM
phenylmethylsulfonyl ﬂuoride, and protease inhibitors (1 tab-
let per 10mL)] and ground using a hand held homogeniser.
Samples were incubated on ice for 5min before two cycles
of freeze-thaw lysis. After a brief vortex, samples were centri-
fuged at 4000 rpm for 3min. The supernatant was removed,
and the pellet (containing the nuclei) was resuspended in
40μL high salt extraction buffer [20mM HEPES, 420mM NaCl,
1mM EDTA, 1mM EGTA, 25% glycerol, 1mM DTT, and prote-
ase inhibitors (1 tablet per 10mL)]. Samples were incubated
on ice for 30min with gentle mixing of the tubes every
5–10min. Samples were centrifuged at 4000 rpm for 5min
at 4°C. The supernatant which now contained the nuclear
proteins was aliquoted into tubes and was stored immediately
at !80°C.
Western blotting
The 20μg of protein from each sample was added to 3μL of
4 × lbs (0.5M Tris–HCl pH 6.8, 20% glycerol, 4% Sodium Dode-
cyl Sulphate (SDS), 0.05% β-mercaptoethanol, and 0.004%
bromophenol blue) and was boiled for 3min. Proteins were
resolved using SDS-polyacrylamide gel electrophoresis at
160 V for 45min. Proteins were transferred to a nitrocellulose
membrane (80mA for 1 h) using semi-dry transfer (biorad).
Membranes were blocked with either 3% Bovine Serum
Albumin (BSA)/Tris-buffered saline and tween 20 (TBST; Tris-
Buffered Saline (TBS), 0.05% tween) overnight at 4°C or with
5% milk/TBST for 1 h at room temperature. Incubation with
primary antibody (1:1000) was carried out in either 3%
BSA/TBST or 0.5% milk/TBST solution at room temperature
for 2 h or overnight at 4°C. Membranes were washed
with TBST, and primary antibody binding was detected
using horseradish-peroxidase-conjugated secondary anti-
bodies (1:2000 to 1:5000). Speciﬁc signal was detected using
enhanced chemiluminescence reagent (GE Healthcare,
Cleveland, OH, USA) and exposure on photographic ﬁlm
(Kodak, Rochester, NY, USA). Films were scanned, and densi-
tometry values were estimated using ImageJ (NIH) software.
All proteins were normalised to alpha-skeletal actin as a load-
ing control, except for FOXO1/3a which, because they were
nuclear protein extracts, were normalised to lamin A/C.
Antibodies
The primary antibodies used in the studywere Akt, pAkt (ser473),
FOXO1, FOXO3a (cell signalling), lamin A/C (Santa Cruz Biotech-
nology Inc., Santa Cruz, CA, USA), dystrophin [MANDYS102
(7D2)], β-dystroglycan [MANDAG2 (7D11)], (Developmental
Studies Hybridoma Bank), β-sarcoglycan (abcam), myosin heavy
chain (fast, sigma), and alpha-skeletal actin (novocaestra). Sec-
ondary antibodies were anti-mouse or anti-rabbit (upstate).
RNA isolation
Total RNA was extracted from approximately 20mg of muscle
using TRIzol (Invitrogen, Waltham, MA, USA) reagent accord-
ing to the manufacturer’s directions. The RNA pellet was
resuspended in diethylpyrocarbonate treated water, and
RNA concentration was determined using a nanodrop spec-
trophotometer (LabTech International, Uckfield, UK). RNA
quality was assessed using 260/280 and 230/260 ratios and
the RNA Integrity Number (RIN) score from the bioanalyzer
2100 instrument (Agilent Technologies, Santa Clara, CA, USA).
Quantitative real-time–polymerase chain reaction
Total RNA was extracted as described previously. cDNA was
prepared using 1μg RNA, TaqMan reverse transcription
reagents (Applied Biosystems, Foster City, CA, USA), and
random hexamer primers (Applied Biosystems). Primers were
designed to span introns using primer express 3.0 software
(Applied Biosystems), and the primers were constructed by
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Invitrogen (Paisley, UK). Primer sequences used were
BNIP3_Fw; GTC AAG TCG GCC GGA AAA TA, BNIP3_Rv; GCG
CTT CGG GTG TTT AAA GA, GABARAPL1_Fw; CCA CCG CAA
GGA GAC AGA AG, GABARAPL1_Rv; GAA AAT GTG ATG ACG
GTG TGT GT, MAFBX_Fw; CCG GCT GTT GGA GCT GAT A,
MAFBX_Rv; TTG GGC GAT GCC ACT CA, MURF1_Fw; GCT
AGG CGT GGC TCT CAT TC, and MURF1_Rv; TCC TGG
ATC AGG CTC GAC TT. Samples were run on an Applied
Biosystems 7900HT fast real-time polymerase chain reaction
(PCR) system (Applied Biosystems) in triplicates of 20μL per
well using SYBR green PCR master mix (Applied Biosystems)
as per manufacturer’s instructions. Expression levels were
normalised to ribosomal 18S RNA, and results were examined
using the delta–delta Threshold Cycle (CT) method.23
Statistical analysis
For analysis of quantitative real-time-PCR and western blot-
ting results, statistical package for the social sciences v19.0
was used. Mathematical transformation (log) was performed
when appropriate. Student’s two tailed t-test, Mann–
Whitney or Kruskal Wallis test was used to compare means
between groups. Contingency tables were constructed where
relevant and were analysed by chi-squared test. Patients
were divided into those who survived > or <1 year post op-
eratively (a meaningful surgical and oncological outcome and
recently advocated by the All Party Parliamentary Group on
Cancer.22 Receiver-operating characteristic (ROC) analysis
was performed using this division, and the cut-off that gave
the highest sensitivity and speciﬁcity was manually selected.
Kaplan–Meier survival curves and log-rank comparison was
used to assess differences in survival between groups. Statis-
tical signiﬁcance was set at a P-value (two-tailed) of ≤0.05.
Results
One hundred seven patients were recruited in total (15 HC
and 92 UGIC patients). Demographics for the entire cohort
are illustrated in Table 1. Biopsies were used according to
availability of tissue for different biomarkers. There were four
separate groups, and the demographics for these are illus-
trated in Supporting Information, Table S1. Supporting Infor-
mation, Figure S1, shows the overlap between groups. No
signiﬁcant differences were evident between these groups
and the entire cohort.
Compared with HC, cancer patients were older [mean (SD)
age 65 (10) vs. 56 (17) years, P = 0.003], had higher average
weight-loss [8.1 (9.3) vs. 0 (0) %, P = 0.001], had lower body
mass index [25.7 (4.0) vs. 28.0 (4.5) kg/m2, P = 0.046], and a
signiﬁcantly had lower KPS [89 (13) vs. 100 (0), P = 0.001,
Table 1A].
Within the cancer patient cohort, cachectic patients com-
pared with non-cachectic patients had a larger proportion of
women (19/51 vs. 7/41, chi-squared P = 0.033), were younger
[63 (9) vs. 68 (9) years, P = 0.022], had shortened median sur-
vival (562 vs. 846 days, P = 0.030), and had a lower body mass
Table 1 Patient demographics for (A) healthy controls and cancer patients (with and without cachexia) and (B) cancer patients surviving ≤ 1 vs.
> 1 year. Results are presented as mean ± standard deviation or categorically except for median survival
Cancer Cancer
A Control All cancer No cachexia Cachexia
n= 15 92 41 51
M/F 8/7 66/26 34/7 32/19**
Age (year) 56±17 65±10* 68±9 63±9**
Weight-loss (%) 0.0± 0.0 8.1±9.3* 0.8± 3.0 13.9±8.6**
Survival (days) – 675 846 562**
BMI (kg/m2) 28.0± 4.5 25.7±4.0* 27.0±4.0 24.6±3.7**
CRP (mg/L) 3.5± 2.7 15.5±31.3 12.0±29.6 18.3±32.6
CRP≥5mg/L (Y/N) 4/11 41/51 15/26 26/25
KPS 100±0 89±13* 92±10 86±14**
B Survival ≤1 year Survival>1 year
n= 27 64
M/F 18/9 48/16
Age (year) 66±10 65±10
Weight-loss (%) 12.0±11.1 6.3± 8.0***
Survival (days) 245 1195***
BMI (kg/m2) 25.3± 3.5 26.0±4.2
CRP (mg/L) 18.0± 36.3 14.6±29.4
CRP ≥ 5mg/L (Y/N) 16/11 25/39
KPS 83±13 91±12***
*P< 0.05 cancer vs. control patients.
**P< 0.05 cachectic vs. non-cachectic patients.
***P< 0.05 survival >1 year vs. survival ≤1 year.
M, male; F, female; BMI, body mass index; CRP, C-reactive protein; KPS, Karnofsky performance score; Y, Yes; N, No.
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index [24.6 (3.7) vs. 27.0 (4.0) kg/m2, P = 0.004]. KPS was also
signiﬁcantly lower in cachectic compared with non-cachectic
patients [86 (14) vs. 92 (10), P = 0.020, Table 1A].
Variability of protein biomarkers in the presence of
cancer and cachexia
Results of the skeletal muscle biomarkers are illustrated in
Figure 1. Level of total Akt protein was reduced in cancer
patients compared with HC [0.49 (0.31) vs. 0.89 (0.17),
P = 0.001], but there was no signiﬁcant difference in pAkt
protein level [0.47 (0.34) vs. 0.29 (0.2), P = 0.104]. However,
the ratio of pAkt to total Akt (indicative of Akt activity) was
increased in cancer patients compared with HC [1.33 (1.04)
vs. 0.32 (0.21), P = 0.002].
Cachectic cancer patients had signiﬁcantly higher levels of
β-dystroglycan than non-cachectic cancer patients [1.01
(0.16) vs. 0.87 (0.20), P = 0.007]. There was also a trend to-
wards increased levels of β-sarcoglycan [0.63 (0.28) vs. 0.55
(0.55), P = 0.052].
Variability of mRNA biomarkers in the presence of
cancer and cachexia
Results of the skeletal muscle biomarkers are illustrated in
Figure 1. There was signiﬁcantly increased expression of
GABARAPL1 in cancer patients compared with HC [1.60 (0.76)
vs. 1.10 (0.57), P = 0.024] and a trend towards an increase in ex-
pression of BNIP3 [1.37 (0.49) vs. 1.07 (0.57), P= 0.058]. No
mRNA biomarkers related to the presence of cachexia.
Variability of biomarkers associated with survival
Patients who survived ≤1 year post operatively compared
with those who survived >1 year had signiﬁcantly higher
average weight-loss [12.0 (11.1) vs. 6.3 (8.0) %, P= 0.007)]and
a lower KPS [83 (13) vs. 91 (12), P= 0.004, Table 1B].
Given that there are no ‘normal’ cut-offs for skeletal muscle
protein levels or mRNA expression for potential markers, ROC
analysis was performed. The most promising candidates from
this analysis were MyHC, dystrophin, and pAkt [area under
the curves were 0.674 (P = 0.069), 0.714 (P = 0.070), and 0.669
(P= 0.068), respectively]. Coordinates of the ROC curves for
these three markers were inspected and a cut-off of ≥0.87 cho-
sen for MyHC to give a sensitivity of 84.8% and speciﬁcity of
46.2%, a cut-off of ≥0.31 chosen for dystrophin to give a sensi-
tivity of 85.0% and speciﬁcity of 55.6%, and a cut-off of ≥0.19
chosen for pAkt to give a sensitivity of 87.5% and speciﬁcity
of 42.3%. Kaplan–Meier survival analysis using these cut-offs
(Figure 2) showed a signiﬁcantly shorter survival for those with
lower compared with higher MyHC levels (median survival 316
vs. 1326days, P = 0.023) and lower compared with higher dys-
trophin levels (median survival 341 vs. 660 days, P = 0.008),
but no signiﬁcant difference between high and low pAkt levels
(P = 0.320). Given the difference in survival for MyHC and dys-
trophin, the demographics of the low vs. higher levels of MyHC
and dystrophin groups were examined (Table 2). None of the
variables differed signiﬁcantly between the groups for either
MyHC or dystrophin.
Discussion
In this biomarker discovery study, we demonstrated suppres-
sion of total Akt protein levels in the skeletal muscle of can-
cer patients but with an increased pAkt/Akt ratio. β-
Dystroglycan appeared to relate to the presence of signiﬁcant
weight-loss in cancer patients. Low MyHC and dystrophin
protein levels both related to shortened survival.
In one of very few similar studies, Schmitt et al.24 examined
protein levels and phosphorylation status of muscle
atrophy/hypertrophy pathway components in eight pancre-
atic cancer patients with cachexia compared with eight
weight-stable cancer or pancreatitis patients.24 They
observed reduced levels of Akt, MyHC, and FOXO1 in the
cachectic group. In the current study, which looked at a much
larger cohort of patients with a variety of UGIC, along with
non-cancer HC, we did not observe any differences in these
markers between cachectic and non-cachectic patients. We
did, however, observe cancer patients (compared with non-
cancer HC) to have a reduction in Akt levels, but with a relative
increase in overall Akt activity (expressed as the ratio of pAkt
to total Akt). It should be noted that whilst FOXO3 antibody
and methodology for determining MyHC levels differed, the
antibodies for FOXO1, Akt, and pAkt were the same between
the two studies and would thus not explain these contrasting
results. Schmitt et al.24 deﬁned cachexia as >10% weight-loss
in 6months, whereas for the current study, cachexia was de-
ﬁned as ≥5% weight-loss1 However, when we analysed our
data according to a 10% weight-loss cut-off, the results for in-
dividual variables did not differ from using a 5% weight-loss
cut-off (data not shown). Therefore, another explanation
would be that total protein turnover is suppressed in cancer
patients25 with a reduction in the available pool of Akt, and
that increased phosphorylation represents a compensatory
mechanism. In support of this, in chronic obstructive pulmo-
nary disease patients with cachexia, an increased ratio of pAkt
to total Akt has also been observed with the suggestion that
this represents an attempt to restore muscle mass.26,27
The muscle-speciﬁc E3 ubiquitin ligases, MuRF-1, and
atrogin-1/MAFbx are commonly used to indicate activation
of the ubiquitin proteasome pathway after the discovery that
they were upregulated in several distinct models of atrophy.6
Likewise, markers of autophagy have been shown to be
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Figure 1 Graphs showing (A) densitometry of protein biomarkers normalised to loading control or (B) delta–delta (Δ) Threshold Cycle (CT)
expression of mRNA biomarkers for healthy controls and cancer patients (with and without cachexia).
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increased in cachectic mice and under the control of FOXO3.18
However, in the current study, FOXO transcription factors and
the ubiquitin E3 ligases were similar between HC and cancer pa-
tients and were not influenced by the presence of cachexia.
Cancer patients did have increased expression of GABARAPL1
and a trend towards increased expression of BNIP3, both of
which play a key role in autophagy. However, we did not see
either of these autophagymarkers significantly relating to survival
or weight-loss. There was evidence of increased β-dystroglycan
protein levels in cachectic patients and a trend towards
increased protein levels of β-sarcoglycan. Whilst dysregulation
of the dystrophin glycoprotein complex is a feature of
muscular dystrophies and has been associated with cachexia,20
increased β-dystroglycan levels were not evident. In a
mouse model of muscular dystrophy treated with an
Adenosine Monophosphate-Activated Protein Kinase (AMPK)
activator, increased utrophin coincided with an increase in
β-dystroglycan and resultant strengthening of the sarco-
lemma.28 It is therefore conceivable that the relationship
between β-dystroglycan and cachexia seen in the current study
represents an attempt at muscle membrane repair as it enters
a more dysregulated state with progressive weight-loss. Given
that the current study is not mechanistic and utrophin was not
investigated as a potential marker, this suggestion is speculative.
It is striking that we demonstrated an association between
low levels of structural muscle proteins and shortened survival.
The lack of signiﬁcant demographic differences between the
low and higher level MyHC/dystrophin groups suggests that
they are bona ﬁde markers of post-operative survival. Lower
levels of these structural proteins may identify a susceptible
population, where muscle structure/membrane integrity has
already started to become compromised. Alterations in mem-
brane structure and integrity have been demonstrated in
C-26 tumour bearing mice and oesophagogastric cancer
patients, which is thought to be due, at least in part, to disrup-
tion of the dystrophin glycoprotein complex.20 This normally
provides a strong mechanical link between the intracellular cy-
toskeleton and extracellular matrix.29 It is also thought that
there is selective targeting of myoﬁbrillar proteins, in particular
MyHC, in cancer cachexia7,10 although a single study has sug-
gested that the selective breakdown of MyHC in mice with can-
cer may be artefactual.30 In addition, myoﬁbrillar degradation
appears to occur in a time-dependent manner.21 Adding to
the concept that membrane damage is important in the path-
ogenesis of cancer cachexia, our laboratory has recently
shown that the presence of various myosin species in the
urine of patients with oesophago-gastric cancer relates to sig-
niﬁcant (>10%) weight-loss.11 Our observations in the current
study that patients with lower skeletal muscle dystrophin or
Figure 2 Kaplan–Meier survival curves for patients with (A) low (<0.87) vs. high (≥0.87) myosin heavy-chain protein levels, log rank P = 0.023 and
(B) low (<0.31) vs. high (≥0.31) dystrophin protein levels, log rank P = 0.008.
Table 2 Patient demographics according to the receiver-operating
characteristic derived cut-offs for (A) myosin heavy-chain and (B) dys-
trophin. Results are presented as mean ± standard deviation or
categorically
A. MyHC Low (<0.87) High (≥0.87)
n= 12 35
M/F 7/5 21/14
Age (year) 63±7 64±10
BMI (kg/m2) 24.9± 4.4 25.4±3.8
Weight-loss (%) 9.8± 7.4 9.6± 12.1
Cachexia (Y/N) 9/3 20/15
CRP (mg/L) 20.3± 41.6 12.1±25.8
CRP ≥ 5mg/L (Y/N) 7/5 14/21
KPS 88.2±10.8 92.1±12.1
B. Dystrophin Low (<0.31) High (≥0.31)
n= 8 21
M/F 5/3 10/11
Age (year) 62±13 63±9
BMI (kg/m2) 26.8± 6.3 25.0±4.3
Weight-loss (%) 9.5± 7.5 9.7±11.3
Cachexia (Y/N) 7/5 14/21
CRP (mg/L) 45.8± 52.3 11.8±22.4
CRP ≥ 5mg/L (Y/N) 5/3 8/13
KPS 82.5±8.9 84.3±15.0
M, male; F, female; BMI, body mass index; CRP, C-reactive protein;
KPS, Karnofsky performance score; Y, Yes; N, No.
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MyHC protein levels are associated with a shortened survival
are entirely consistent with this concept. Therefore, measure-
ments of these structural elements in skeletal muscle appear to
be suitable biomarkers relating to survival in UGIC cancer patients.
By comparing cachectic, non-cachectic, and HC groups, this
study evaluates the potential of certain variables to act as bio-
markers of cachexia. However, it is not possible to determine
the precise role of these variables in cachexia by comparing
the cachectic with non-cachectic groups. The patients without
cachexia at diagnosis represent a mixed group some of whom
will remain weight-stable, but a signiﬁcant other group will
progress to cachexia and is therefore in a pre-cachectic state.
This heterogeneity within the weight-stable group potentially
masked changes in some variables that may play a role in
development of cachexia/pre-cachexia. In order to further
explore this area, repeated assessments of patients would
be required to determine which individuals progress to losing
weight after the initial biopsy. Whilst longitudinal studies in
human cancer cachexia may be informative in this regard,
they are difﬁcult to carry out owing to the requirements for
multiple assessments/tissue samples in a frail population. In
addition, there may be varying responses among patients to
adjuvant chemoradiotherapy, the inﬂuence of surgery, post-
operative complications, concurrent illnesses (e.g. infections),
and selective attrition that will add to the complexity of
interpreting such studies.
Although there were no statistically signiﬁcant differences be-
tween the four patient groups (see Supporting Information,
Table S1) and entire cohort, it is possible that more subtle varia-
tions within the groups inﬂuenced some of the results. Gender
or differences in underlying tumour type, site, or stagemay inﬂu-
ence progression of cachexia and potentially, levels of the bio-
markers assessed. In the current study, subdivision of patients
into these categories resulted in numbers too small for meaning-
ful analysis with, for example, only one or two female non-
cachectic pancreatic cancer patients in some biomarkers. Whilst
the impact of such factors has not been thoroughly investigated
to date, in the future, a more conclusive identiﬁcation of bio-
markers would probably require a more complete set of markers
for one type of cancer and gender division from the outset.
The potential biomarkers of cachexia in the current study
were selected from evidence relating predominantly to muscle
wasting in animal models. The lack of association of biomarkers
with cachexia may therefore simply reﬂect differences be-
tween animal and human cancer cachexia. Whereas the major-
ity of animal models of cachexia undergoes rapid and profound
weight-loss, human cancer cachexia is a chronic disease pro-
cess. Furthermore, in humans, there will be added confounding
factors such as level of baseline physical activity, bed rest, the
presence of co-morbidities, dietary preferences, personal moti-
vation, and sickness behaviour.
The majority of potential biomarkers that was evaluated
related to protein degradation rather than synthetic path-
ways. There is reasonable evidence to suggest that in muscle
atrophy associated with ageing/bed-rest, suppression of pro-
tein synthesis is of greater importance than increased degra-
dation.31 Furthermore, in patients with UGIC, our group
recently found evidence of suppression of muscle protein turn-
over.25 It may be that future studies investigating biomarkers
selected from anabolic pathways may identify candidates that
relate more strongly to cachexia. Alternatively, changes in mus-
cle at the molecular level may not have a strong inﬂuence on
muscle phenotype. Evidence of such dissociation has been
demonstrated by Greenhaff et al.32 in the skeletal muscle of
healthy men.32 Whether this also occurs in the context of hu-
man cancer cachexia remains to be elucidated.
In conclusion, many of the key components of known
muscle wasting pathways do not transpose directly to being
robust biomarkers of cachexia. Skeletal muscle Akt protein
levels/phosphorylation status and GABARAPL1 expression
are biomarkers relating to cancer and possibly early cachexia.
β-Dystroglycan is a biomarker of weight-loss in cancer
patients and MyHC and dystrophin are biomarkers associated
with survival. This study highlights the complexity of bio-
marker research and provides impetus for further validation
and discovery studies in order to identify robust diagnostic
biomarkers and potential therapeutic targets in patients with
cancer cachexia.
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